XML 24 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Total National Health Investors Stockholders’ Equity
Common Stock
Capital in Excess of Par Value
Retained Earnings
Cumulative Dividends
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021     45,850,599        
Beginning balance, amount at Dec. 31, 2021 $ 1,516,983 $ 1,507,083 $ 459 $ 1,591,182 $ 2,416,713 $ (2,501,271) $ 9,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interests (1,015)           (1,015)
Net income, excluding loss attributable to redeemable noncontrolling interest 66,344 66,403     66,403   (59)
Reclassification of redeemable noncontrolling interest 1,030           1,030
Equity issuance cost (80) (80)   (80)      
Taxes related to net settlement of equity awards $ (288) (288)   (288)      
Shares issued on stock options exercised (in shares)     6,497        
Repurchases of common stock (in shares) (2,500,000)   (2,468,354)        
Repurchases of common stock $ (151,951) (151,951) $ (25)   (151,926)    
Share-based compensation 8,613 8,613   8,613      
Dividends declared (159,555) (159,555)       (159,555)  
Ending balance (in shares) at Dec. 31, 2022     43,388,742        
Ending balance, amount at Dec. 31, 2022 1,280,081 1,270,225 $ 434 1,599,427 2,331,190 (2,660,826) 9,856
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling interests capital contribution 2,051           2,051
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interests (1,286)           (1,286)
Net income, excluding loss attributable to redeemable noncontrolling interest 135,472 135,654     135,654   (182)
Equity issuance cost $ (275) (275)   (275)      
Grants of restricted stock (in shares)     21,000        
Shares issued on stock options exercised (in shares)     99        
Repurchases of common stock (in shares) 0            
Share-based compensation $ 4,605 4,605   4,605      
Dividends declared $ (156,257) (156,257)       (156,257)  
Ending balance (in shares) at Dec. 31, 2023 43,409,841   43,409,841        
Ending balance, amount at Dec. 31, 2023 $ 1,264,391 1,253,952 $ 434 1,603,757 2,466,844 (2,817,083) 10,439
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling interests capital contribution 70           70
Distributions declared to noncontrolling interests, excluding attributable to redeemable noncontrolling interests (1,167)           (1,167)
Net income, excluding loss attributable to redeemable noncontrolling interest 137,555 137,985     137,985   (430)
Equity issuance cost $ (1,401) (1,401)   (1,401)      
Issuance of common stock, net (in shares) 2,065,878            
Issuance of common stock, net $ 142,394 142,394 $ 21 142,373      
Reclassification of asset related to forward equity sale agreement (6,261) (6,261)   (6,261)      
Taxes related to net settlement of equity awards (in shares)     (230)        
Taxes related to net settlement of equity awards $ (5,819) (5,819)   (5,819)      
Grants of restricted stock (in shares)     15,000        
Shares issued on stock options exercised (in shares) 1,065,119   197,453        
Shares issued on stock options exercised $ 2 2 $ 2        
Repurchases of common stock (in shares) 0            
Share-based compensation $ 4,182 4,182   4,182      
Dividends declared $ (158,559) (158,559)       (158,559)  
Ending balance (in shares) at Dec. 31, 2024 45,687,942   45,687,942        
Ending balance, amount at Dec. 31, 2024 $ 1,375,387 $ 1,366,475 $ 457 $ 1,736,831 $ 2,604,829 $ (2,975,642) $ 8,912